Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience
- DOI
- 10.1016/j.diabres.2026.113648
- Published
- 2026-11
- Container
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.diabres.2026.113648,
title = {Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience},
author = {Sanjeev Kumar Patel and Swati Dubey and Ankita Tiwari},
year = {2026},
journal = {Diabetes Research and Clinical Practice},
doi = {10.1016/j.diabres.2026.113648},
url = {https://doi.org/10.1016/j.diabres.2026.113648}
}RIS
TY - JOUR TI - Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience AU - Sanjeev Kumar Patel AU - Swati Dubey AU - Ankita Tiwari PY - 2026 JO - Diabetes Research and Clinical Practice DO - 10.1016/j.diabres.2026.113648 UR - https://doi.org/10.1016/j.diabres.2026.113648 ER -
APA
Patel, S. K., Dubey, S., & Tiwari, A. (2026). Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2026.113648
Source records
- crossref · retrieved 2026-11-09T06:43:26.764Z